A 64-year-old man was diagnosed with limited cutaneous systemic sclerosis 5 years prior to this report. His sclerotic skin symptoms did not respond to oral low-dose prednisone (5-10 mg/day). Five years after the diagnosis, the patient presented with leukocytosis 3.8 × 109/L in a routine blood test, and was finally diagnosed with chronic-phase chronic myelogenous leukemia (CML). The leukemia responded optimally to initial dasatinib, and a complete cytogenetic response was achieved after 6 months of therapy. His skin symptoms dramatically improved in parallel with dasatinib therapy, as indicated by a decrease in the modified Rodnan skin score, from 12 points at diagnosis to 2 after 9 months. It has been reported that imatinib, a first-generation tyrosine kinase inhibitor, improves skin sclerosis in some patients with systemic sclerosis. To the best of our knowledge, this is the first report of simultaneous improvement of CML and limited cutaneous systemic sclerosis in response to dasatinib. Further study of the mechanism of action of dasatinib is crucial.

中文翻译：

---

达沙替尼治疗慢性粒细胞性白血病可改善全身性硬化症的皮肤症状。

在此报告之前的5年，一名64岁的男性被诊断患有有限的皮肤系统性硬化症。他的硬化性皮肤症状对口服低剂量泼尼松（5-10 mg /天）无反应。诊断五年后，该患者在常规血液检查中出现白细胞增多症3.8×109 / L，最终被诊断为慢性慢性粒细胞性白血病（CML）。白血病对初始达沙替尼的反应最佳，在治疗6个月后达到了完全的细胞遗传学反应。与达沙替尼治疗同时，他的皮肤症状显着改善，如改良的Rodnan皮肤评分从诊断时的12分降低到9个月后的2分所表明。据报道，第一代酪氨酸激酶抑制剂伊马替尼可改善某些系统性硬化症患者的皮肤硬化症。据我们所知，这是对达沙替尼治疗可同时改善CML和限制皮肤全身硬化的首次报道。进一步研究达沙替尼的作用机制至关重要。